Abstract
Background: Sarcoidosis is a multisystem granulomatous disease with a neglected but high prevalence of life-threatening cardiac involvement.
Discussion: The clinical presentation of Cardiac Sarcoidosis (CS) depends upon the location and extent of the granulomatous inflammation, with left ventricular free wall the most common location followed by interventricular septum. The lack of a diagnostic gold standard and the unpredictable risk of sudden cardiac death pose serious challenges for the validation of accurate and effective screening test and the management of the disease. In the last few years advanced cardiac imaging modalities such as Cardiac Magnetic Resonance (CMR) and Positron Emission Tomography (PET) have significantly improved our knowledge and understanding of CS, and have also contributed in risk stratification, assessment of inflammatory activity and therapeutic monitoring of the disease.
Conclusion: In this review, we will discuss the state of the art in the diagnosis of CS focusing on the role and importance of multi-modality cardiac imaging.
Keywords: Cardiac sarcoidosis, magnetic resonance imaging, positron emission tomography, echocardiography, multimodality cardiac imaging, single photon emission computed tomography.
Graphical Abstract
[1]
Ipek E, Demirelli S, Ermis E, Inci S. Sarcoidosis and the heart: A review of the literature. Intractable Rare Dis Res 2015; 4(4): 170-80.
[3]
Freeman Andrew, Weinberger Howard. Cardiac Sarcoidosis: Key concepts in Pathogenesis, Disease Management, and Interesting Cases. Switzerland: Springer 2015.
[4]
Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58(6): 1204-11.
[5]
Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976; 278: 455-69.
[6]
Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: Epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131(7): 624-32.
[7]
Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88(9): 1006-10.
[8]
Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63(1): 86-108.
[9]
Lagana SM, Parwani AV, Nichols LC. Cardiac sarcoidosis: A pathology-focused review. Arch Pathol Lab Med 2010; 134(7): 1039-46.
[10]
Lynch JP 3rd, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: Evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med 2014; 35(3): 372-90.
[11]
Tchernev G, Tana C, Schiavone C, Cardoso JC, Ananiev J, Wollina U. Sarcoidosis vs. Sarcoid-like reactions: The two sides of the same coin? Wien Med Wochenschr 2014; 164(13-14): 247-59.
[12]
Tchernev G, Chokoeva AA, Tana C, Patterson JW, Wollina U, Lotti T. Sarcoid sine sarcoidosis? A classificative, semantic and therapeutic dilemma. J Biol Regul Homeost Agents 2015; 29(Suppl. 1): 33-4.
[13]
Sekhri V, Sanal S, Delorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: A comprehensive review. Arch Med Sci 2011; 7(4): 546-54.
[14]
Hamzeh N, Steckman DA, Sauer WH, Judson MA. Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol 2015; 12(5): 278-88.
[15]
Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Med 2009; 104(4): 571-7.
[16]
Houston BA, Mukherjee M. Cardiac sarcoidosis: Clinical manifestations, imaging characteristics, and therapeutic approach. Clin Med Insights Cardiol 2014; 8(Suppl. 1): 31-7.
[17]
Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 2015; 16(9): 949-58.
[18]
Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther 2016; 6(1): 50-63.
[20]
Isobe M, Tezuka D. Isolated cardiac sarcoidosis: Clinical characteristics, diagnosis and treatment. Int J Cardiol 2015; 182: 132-40.
[21]
Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 2008; 133(6): 1426-35.
[22]
Freeman AM, Curran-Everett D, Weinberger HD, et al. Predictors of cardiac sarcoidosis using commonly available cardiac studies. Am J Med 2013; 112(2): 280-5.
[23]
Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulom Dis 2007; 27: 89-102.
[24]
Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31(1): 19-27.
[25]
Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11(7): 1305-23.
[26]
Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2012; 141(1): 154-62.
[27]
Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H. Defining organ involvement in sarcoidosis: The ACCESS proposed instrument. ACCESS research group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16(1): 75-86.
[28]
Burstow DJ, Tajik AJ, Bailey KR, DeRemee RA, Taliercio CP. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989; 63(7): 478-82.
[29]
Sun BJ, Lee PH, Choi HO, et al. Prevalence of echocardiographic features suggesting cardiac sarcoidosis in patients with pacemaker or implantable cardiac defibrillator. Korean Circ J 2011; 41(6): 313-20.
[30]
McKenna W. Cardiac Sarcoidosis. In: Post T, editor. UpToDate. UpToDate, Whaltam, MA. (Accessed on July 25, 2016)
[31]
Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arth Res Therapy 2007; 9(Suppl. 2): S8.
[32]
Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010; 52(4): 336-46.
[33]
Uemura A, Morimoto S, Kato Y, et al. Relationship between basal thinning of the interventricular septum and atrioventricular block in patients with cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22(1): 63-5.
[34]
Bargout R, Kelly RF. Sarcoid heart disease: Clinical course and treatment. Int J Cardiol 2004; 97(2): 173-82.
[35]
Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol 2010; 55(17): 1769-79.
[36]
Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82(4): 537-40.
[37]
Agarwal A, Sulemanjee NZ, Cheema O, Downey FX, Tajik AJ. Cardiac sarcoid: A chameleon masquerading as hypertrophic cardiomyopathy and dilated cardiomyopathy in the same patient. Echocardiography 2014; 31(5): E138-41.
[38]
Sankaranarayanan R. E JF, C JG. Mimics of hypertrophic cardiomyopathy - Diagnostic clues to aid early identification of phenocopies. Arrhythm Electrophysiol Rev 2013; 2(1): 36-40.
[39]
Aggeli C, Felekos I, Tousoulis D, Gialafos E, Rapti A, Stefanadis C. Myocardial mechanics for the early detection of cardiac sarcoidosis. Int J Cardiol 2013; 168(5): 4820-1.
[40]
Bulkley BH, Rouleau JR, Whitaker JQ, Strauss HW, Pitt B. The use of 201thallium for myocardial perfusion imaging in sarcoid heart disease. Chest 1977; 72(1): 27-32.
[41]
Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000; 94(3): 193-9.
[42]
Kinney EL, Caldwell JW. Do thallium myocardial perfusion scan abnormalities predict survival in sarcoid patients without cardiac symptoms? Angiology 1990; 41(7): 573-6.
[43]
Kinney EL, Jackson GL, Reeves WC, Zelis R. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients. Am J Med 1980; 68(4): 497-503.
[44]
Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 2003; 44(7): 1030-6.
[45]
Nakazawa A, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest 2004; 126(4): 1372-6.
[46]
Nunes H, Freynet O, Naggara N, Soussan M, Weinman P, Diebold B, et al. Cardiac sarcoidosis. Semin Respir Crit Care Med 2010; 31(4): 428-41.
[47]
Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: Environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170(12): 1324-30.
[48]
Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124(3): 922-8.
[49]
Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129(5): 1246-52.
[51]
Holly TA, Abbott BG, Al-Mallah M, et al. Single photon-emission computed tomography. J Nucl Cardiol 2010; 17(5): 941-73.
[52]
Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol 2011; 16(2): 140-7.
[53]
Yodogawa K, Seino Y, Shiomura R, et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol 2013; 62(5): 320-5.
[54]
Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005; 95(1): 143-6.
[55]
Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45(12): 1989-98.
[56]
Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. Curr Cardiol Rep 2014; 55(1): 99-106.
[57]
Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35(5): 933-41.
[58]
Paz YE, Bokhari S. The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy. Int J Cardiovasc Imaging 2014; 30(2): 431-8.
[59]
Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: Comparison with radionuclide imaging. AJR Am J Roentgenol 2005; 185(1): 110-5.
[60]
Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013; 6(4): 501-11.
[61]
Paajanen H, Brasch RC, Schmiedl U, Ogan M. Magnetic resonance imaging of local soft tissue inflammation using gadolinium-DTPA. Acta Radiol 1987; 28(1): 79-83.
[62]
Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45(10): 1683-90.
[63]
Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120(20): 1969-77.
[64]
Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 2014; 146(4): 1064-72.
[65]
Isted A, Grigoratos C, Bratis K, Carr-White G, Nagel E, Puntmann VO. Native T1 in deciphering the reversible myocardial inflammation in cardiac sarcoidosis with anti-inflammatory treatment. Int J Cardiol 2016; 203: 459-62.
[66]
Yang Y, Safka K, Graham JJ, et al. Correlation of late gadolinium enhancement MRI and quantitative T2 measurement in cardiac sarcoidosis. J Magnetic Resonance Imaging: JMRI 2014; 39(3): 609-16.
[67]
Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110(7): 520-7.
[68]
Zaidi H, Del Guerra A. An outlook on future design of hybrid PET/MRI systems. Med Phys 2011; 38(10): 5667-89.
Article Metrics
32
3